144 related articles for article (PubMed ID: 27635409)
21. Acute Pancreatitis-Induced Euglycemic Diabetic Ketoacidosis.
Chaudhry A; Biggiani C; Afzal M; Chaudhry S; Vwich Y
Cureus; 2021 Jun; 13(6):e15949. PubMed ID: 34336446
[TBL] [Abstract][Full Text] [Related]
22. The Use of SGLT-2 Inhibitors Coupled With a Strict Low-Carbohydrate Diet: A Set-Up for Inducing Severe Diabetic Ketoacidosis.
Guirguis H; Beroukhim Afrahimi S; Pham C
Clin Med Insights Case Rep; 2022; 15():11795476221090045. PubMed ID: 35418794
[TBL] [Abstract][Full Text] [Related]
23. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
[TBL] [Abstract][Full Text] [Related]
24. Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use.
Melnick S; Rajagopalan P; Lynn T; Donato A
J Community Hosp Intern Med Perspect; 2018; 8(5):315-316. PubMed ID: 30357044
[No Abstract] [Full Text] [Related]
25. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review.
Thiruvenkatarajan V; Meyer EJ; Nanjappa N; Van Wijk RM; Jesudason D
Br J Anaesth; 2019 Jul; 123(1):27-36. PubMed ID: 31060732
[TBL] [Abstract][Full Text] [Related]
26. Alpelisib-Induced Diabetic Ketoacidosis: A Case Report and Review of Literature.
Carrillo M; Rodriguez RM; Walsh CL; Mcgarvey M
AACE Clin Case Rep; 2021; 7(2):127-131. PubMed ID: 34095470
[TBL] [Abstract][Full Text] [Related]
27. Post-Operative Euglycemic Diabetic Ketoacidosis in a Patient With SGLT-2 Inhibitor Use and Recent Sleeve Gastrectomy.
Smith A; Holtrop J; Sadoun M
Cureus; 2021 Apr; 13(4):e14297. PubMed ID: 33968511
[TBL] [Abstract][Full Text] [Related]
28. Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report.
Mendelsohn RA; Taveras AN; Mazer BA; Clayton LM
Clin Pract Cases Emerg Med; 2020 Aug; 4(3):389-392. PubMed ID: 32926693
[TBL] [Abstract][Full Text] [Related]
29. SGLT-2 Inhibitors-a Culprit of Diabetic Ketoacidosis Postbariatric Surgery.
Iqbal QZ; Mishiyev D; Niazi MR; Zia Z; Sattar SBA; Jahanghir A; Quyyumi S
Case Rep Crit Care; 2020; 2020():8817829. PubMed ID: 33204542
[TBL] [Abstract][Full Text] [Related]
30. RE: DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Bell DSH
Endocr Pract; 2018 Jan; 24(1):126. PubMed ID: 29368970
[No Abstract] [Full Text] [Related]
31. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
32. A Case of Severe Acute Kidney Injury Exacerbated by Canagliflozin in a Patient with Type 2 Diabetes.
Hassani-Ardakania K; Lipman ML; Laporta D; Yu OHY
Case Rep Endocrinol; 2019; 2019():8639629. PubMed ID: 31275667
[TBL] [Abstract][Full Text] [Related]
33. People with type 1 diabetes using short acting analogue insulins are less dehydrated than those with using human soluble insulin prior to onset of diabetic ketoacidosis.
Dhatariya K
Med Hypotheses; 2008 Nov; 71(5):706-8. PubMed ID: 18694627
[TBL] [Abstract][Full Text] [Related]
34. EUGLYCEMIC DIABETIC KETOACIDOSIS (EDKA) IN A PATIENT RECEIVING DAPAGLIFLOZIN.
Sethi SM; Vohra M; Ali SA
Acta Endocrinol (Buchar); 2021; 17(2):266-269. PubMed ID: 34925578
[TBL] [Abstract][Full Text] [Related]
35. Candidemia Following Ureteric Stent Placement in a Patient With Type 2 Diabetes Treated With Canagliflozin.
Raj R; Hendrie J; Jacob A; Adams D
Front Endocrinol (Lausanne); 2019; 10():20. PubMed ID: 30761087
[TBL] [Abstract][Full Text] [Related]
36. Model analysis of effect of canagliflozin (Invokana), a sodium-glucose cotransporter 2 inhibitor, to alter plasma 1,5-anhydroglucitol.
Fortuna D; McCloskey LJ; Stickle DF
Clin Chim Acta; 2016 Jan; 452():138-41. PubMed ID: 26569347
[TBL] [Abstract][Full Text] [Related]
37. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
38. Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern.
Gelaye A; Haidar A; Kassab C; Kazmi S; Sinha P
Case Rep Crit Care; 2016; 2016():1656182. PubMed ID: 27088018
[TBL] [Abstract][Full Text] [Related]
39. Ketoacidosis With Canagliflozin Prescribed for Phosphoinositide 3-Kinase Inhibitor-Induced Hyperglycemia: A Case Report.
Bowman C; Abramson V; Wellons M
J Investig Med High Impact Case Rep; 2017; 5(3):2324709617725351. PubMed ID: 28856166
[No Abstract] [Full Text] [Related]
40. Post-surgical Euglycemic Diabetic Ketoacidosis in a Patient on Empagliflozin in the Intensive Care Unit.
Bteich F; Daher G; Kapoor A; Charbek E; Kamel G
Cureus; 2019 Apr; 11(4):e4496. PubMed ID: 31259114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
